FDA Investigator Mra V Millarw
Mra V Millarw has conducted inspections on 12 sites in 8 countries as of 19 Jun 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
12
Last Inspection Date:
19 Jun 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
Ireland,
United Kingdom of Great Britain and Northern Ireland,
Poland,
Romania,
Germany,
India,
Switzerland,
Denmark
FDA Investigators that have inspected at least one site in common with Mra V Millarw:
Azza Talaat,
Barbara M Frazier,
Bijoy Panicker,
Bo Chi, PhD,
Brandon C Heitmeier,
Brian M Janelsins, PhD,
Bruce H Mccullough,
Burnell M Henry,
Charles R Cote, RIC,
Christina Capacci Daniel, PhD,
Christopher Downey, PhD,
Christopher T Middendorf,
Constance Y Fears,
Courtney N Long,
Darren S Brown,
David S Jackson,
Deborah Schmiel, PhD,
Debra I Love,
Demitria J Xiradakis,
Dennis Cantellops Paite,
Doan T Nguyen, PharmD,
Douglas C Kovacs,
Dr. Barbara D Paul, PhD,
Dr. Ralph M Bernstein, PhD,
Dr. Robert C Horan, MD,
Elizabeth B Griffin,
Ephrem Hunde, PhD,
Eric M Mueller, PharmD,
Frederick F Razzaghi,
Jared P Stevens,
Jennifer C Adams,
John A Podsadowski,
Jose Acruz Gonzalez,
Jose M Cayuela,
Justine Tomasso,
Kenneth M Gordon,
Kevin P Foley,
LCDR Chad N Thompson,
Mark E Parmon,
Mark W Rivero,
Meisha R Sampson,
Melba Trivera Clavell,
Michael P Sheehan,
Michael R Klapal,
Michael Shanks, MS,
Michele L Forster, PhD,
Michele Perry Williams,
Miguel A Martinez Perez,
Mra Digiuliod,
Neal L Adams,
Omotunde O Osunsanmi,
Paraluman S Leonin,
Parul M Patel,
Paul L Bellamy,
Philip F Istafanos, DMV, MS,
Rashmi Rawat, PhD,
Rebecca Rodriguez,
Regina T Brown,
Reyes Candau Chacon, PhD,
Richard H Penta,
Robert C Steyert,
Robert D Tollefsen,
Russell J Glapion,
Satheesh Thomas,
Shawn E Larson,
Steven Fong, MS, PhD,
Susan M Jackson,
Susan T Hadman,
Tamil Arasu, PhD,
Terri L Dodds,
Theresa Kirkham (NMI),
Thomas J Arista,
Tiffani D Wilson,
Torrance J Slayton,
Travis S Bradley,
Wayne E Seifert,
Xianghong Jing (Emily), PhD,
Xiaokuang Lai, PhD,
Yehualashet A Gessesse,
Zhong Li, PhD
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more